Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Latest Generation Random Analyzer System Unveiled at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 01 Aug 2013
The latest generation random access clinical chemistry and immunochemistry analyzer is receiving its debut at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.

The Siemens Healthcare Diagnostics (Tarrytown, NY, USA) is unveiling the advanced VersaCell X3 system at the Clinical Lab Expo. More...


The newest model of Siemens’s longstanding VersaCell System, the new VersaCell X3 Solution now offers the benefits of automation without the space or budget considerations of a track-based system. VersaCell X3 Solution’s arrival compliments the recent launch of the Siemens Aptio Automation platform, designed for the growing needs of medium- to very high-volume laboratories.

The VersaCell X3 Solution delivers several advantages. The new platform maintains its small footprint and upright design, but now connects up to three Siemens analyzers through a single robotic sample interface for increased productivity gains. By supporting a customized mix of chemistry, immunoassay and/or integrated systems and associated assay menus, VersaCell X3 Solution helps labs to reduce operator sample handling, better prioritize staff work and eliminate pre- and post-analytical processing—all through one-touch sample management.

A new priority drawer on the VersaCell X3 Solution provides eight new STAT positions and frees up 50 sample positions for routine processing, enhancing STAT management and increasing overall sample routing flexibility. Modifications to VersaCell X3 Solution’s signature robotic arm also enable it to support both rounded and flat-bottom tubes, and the incorporation of a docking plate reduces service intervention time for all connected systems. A centralized screen on VersaCell X3 Solution provides consolidated, single-operator access to all connected analyzers, and further data consolidation is achievable through a connection to Siemens’ CentraLink Data Management System.

“Siemens strives to be a trusted partner for labs of all sizes and central to that goal is helping them identify and capitalize on their workflow excellence potential,” said Dave Hickey, CEO of the IT Business Unit at Siemens Healthcare Diagnostics. “The introduction of VersaCell X3 Solution is yet another way Siemens delivers on this mission through its ability to help labs streamline nonautomated environments and enhance operational efficiency, all at a cost they can justify.”

Related Links:
Siemens Healthcare Diagnostics


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.